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Strengths and limitations of this study
 ► This phase II trial is powered to detect effects of 
melatonin on subjective sleep disturbance.
 ► The study is limited to a single site in Northeast 
Scotland.
 ► The randomised cross- over design will expose all 
participants to the study drug, maximising data 
available for analysis while reducing the influence of 
confounding covariates.
 ► We are using only one dose of melatonin (2 mg) 
for 6 weeks, but there are uncertainties about the 
optimal dose and dosing duration in our study 
population.
 ► Longitudinal actigraphy monitoring and daily self- 
reported outcome measures will improve objectivity, 
reduce recall bias and enable detailed analysis of 
within- subject differences.
AbStrACt
Introduction Chronic pain is prevalent, and approximately 
half of patients with chronic pain experience sleep 
disturbance. Exogenous melatonin is licensed to treat 
primary insomnia and there is some evidence for analgesic 
effects of melatonin.
The aim of this study is to investigate the effects of 
oral melatonin (as Circadin) 2 mg at night in adults 
with severe non- malignant pain of at least 3 months’ 
duration.
Methods and analysis We will conduct a randomised 
double- blind placebo- controlled cross- over study. 
The primary outcome is sleep disturbance. Secondary 
outcomes are pain intensity, actigraphy, fatigue, reaction 
time testing, serum melatonin and endogenous opioid 
peptide levels along with patient views about study 
participation.
We aim to recruit 60 patients with severe chronic pain 
(average pain intensity ≥7 on the Brief Pain Inventory (BPI)) 
from a tertiary referral pain clinic in Northeast Scotland. 
Participants will be randomised to receive melatonin 
(as modified release Circadin) 2 mg daily for 6 weeks 
or placebo, followed by a 4- week washout period, then 
6 weeks treatment with the treatment they did not receive. 
Participants will complete the Verran Snyder- Halpern 
Sleep Scale, Pittsburgh Sleep Quality Index, Pain and Sleep 
Questionnaire 3- item index, BPI and psychomotor vigilance 
reaction time testing at 6 points over 20 weeks. Actigraphy 
watches will be used to provide objective measures of 
sleep duration and latency and other sleep measures and 
will prompt patients to report contemporaneous pain and 
fatigue scores daily.
Cross- over analyses will include tests for effects 
of treatment, period, treatment–period interaction 
(carryover effect) and sequence. Within- patient effects 
and longitudinal data will be analysed using mixed linear 
models, accounting for potential confounders.
Ethics and dissemination Approved by Office for 
Research Ethics Committees Northern Ireland, reference 
19/NI/0007. Results will be published in peer- reviewed 
journals and will be presented at national and international 
conferences.
trial registration number ISRCTN12861060
IntroduCtIon
Chronic non- malignant pain is a major clin-
ical problem affecting approximately 20% of 
the European population.1 Pain and sleep 
disturbance often occur together. Epide-
miological reports suggest that over 50% of 
individuals with chronic pain experience 
disturbed sleep.2–5 The risk of poor sleep 
quality increases as patient- reported pain 
intensity increases.6 Both chronic pain and 
sleep disturbance independently diminish 
quality of life and have a detrimental effect 
on mental health and well- being.5 Chronic 
pain and sleep disorders are challenging to 
manage, and pharmacological options for 
treating sleep disturbance in individuals with 
chronic pain are limited.7
Current understanding is that pain and 
sleep are inextricably linked via a bidirec-
tional relationship: pain disrupts sleep and 
poor quality or shorter duration of sleep can 
increase sensitivity to painful stimuli.8 Poor 
sleep quality and insufficient sleep duration 
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are risk factors for the development of chronic pain.8 9 
Neurobiological mechanisms linking sleep and pain are 
not fully understood but are likely to involve multiple 
hormonal, chemical and immunological pathways.8 10
Melatonin is a neurohormone, mainly secreted by the 
pineal gland. Melatonin secretion is stimulated by dark-
ness and suppressed by light, with peak levels occurring 
between 0200 and 0400 hours. Melatonin is a key regu-
lator of circadian biological rhythms. Meta- analysis shows 
that treatment of primary sleep disorders with exoge-
nous melatonin reduces sleep latency and improves total 
sleep time and sleep quality.11 The only licensed form 
of exogenous melatonin in the EU is a modified release 
form (Circadin) to treat primary insomnia in adults over 
the age of 55.12 Immediate release formulations can be 
prescribed on a named patient basis to treat sleep disor-
ders in children and young people with attention- deficit 
hyperactivity disorder.13
Melatonin has a wide range of functions in addition 
to its role in the sleep–wake cycle. It is an antioxidant,14 
and has anti- inflammatory,15 16 oncostatic17 and anxio-
lytic properties.18 There is emerging evidence that mela-
tonin also has analgesic effects. The exact mechanisms 
are not known, but β-endorphins, gamma- aminobutyric 
acid and opioid receptors, and nitric oxide- arginine 
pathways have all been implicated.19 Pain sensitivity 
has a circadian pattern,20 and chronic pain syndromes 
can be associated with desynchronisation of circadian 
rhythms.21
There have been many preclinical reports of the bene-
fits of melatonin on pain19 22 23 but few clinical trials in 
patients. There have been some trials of melatonin in 
specific types of pain. In patients with fibromyalgia, adju-
vant use of melatonin was shown to be useful in reducing 
the fibromyalgia impact score.24 In patients with migraine, 
melatonin was as effective at reducing migraine attacks 
as amitriptyline.25 Our study will determine the effect of 
melatonin on both sleep parameters and pain in patients 
with chronic pain of a variety of causes using a cross- over 
trial to allow within- subject comparisons. Melatonin is a 
safe and well- tolerated agent, even at high doses.26 It is 
an accepted therapy for sleep disturbance and indeed 
Circadin is licensed for insomnia in older subjects. Mela-
tonin could have advantages in the chronic pain popu-
lation due to its potential to impact both sleep and pain 
intensity together.
This paper describes the protocol for a phase II 
randomised, double blind, placebo- controlled, cross- over 
trial of exogenous melatonin (as oral Circadin, 2 mg) in 
patients with severe chronic pain. We consider chronic 
pain to be pain that has persisted for at least 3 months and 
define severe pain as self- reported average pain intensity 
of ≥7 on the Brief Pain Inventory (BPI). Previous studies 
of Circadin specifically report efficacy of 2 mg nightly in 
terms of sleep latency in patients with primary insomnia, 
with effects seen after 3 weeks.27 28 There is little existing 
data on the effects of melatonin in patients with chronic 
pain.
The primary objective is to investigate the effects of 
exogenous melatonin on sleep in individuals with severe 
chronic pain. Secondary objectives are to assess the effect 
of Circadin on pain intensity, activity levels and fatigue. 
We will also investigate intervention fidelity and phar-
macodynamics by measuring serum levels of melatonin 
and its major metabolite, 6- hydroxymelatonin sulfate. We 
hypothesise that exogenous melatonin will improve sleep 
duration and quality and reduce pain intensity levels in 
individuals with chronic pain. We will also investigate the 
opioid system as a potential pathway of analgesic effect 
by measuring endogenous opioid peptide levels. We will 
assess our study procedures for participant acceptability 
and determine the feasibility of performing a future 
large- scale multicentre phase II trial.
MEthodS And AnAlySIS
Study design and intervention
This is a single- centre, double- blind, randomised, placebo- 
controlled phase II trial that will recruit patients from 
a tertiary referral pain management clinic in National 
Health Service (NHS) Grampian (Northeast Scotland). 
Participants will be randomised to receive either 2 mg 
slow release melatonin nightly, as Circadin or an iden-
tical placebo for 6 weeks, followed by a 4- week washout 
period and then a further 6 weeks of either placebo or 
Circadin (whichever they did not initially receive—cross- 
over design). Participants will be in the trial for a total of 
20 weeks. A study flow diagram is presented in figure 1. 
This protocol paper follows the Standard Protocol Items: 
Recommendation for Interventional Trials guidelines.29 
We do not plan any modifications to the intervention 
during the study period. Participants can withdraw at any 
time. Data and samples obtained will be retained with 
consent, and any reasons given for withdrawal will be 
recorded.
Sample selection
We will include adult patients (18 years or older) with non- 
malignant pain of ≥3 months duration who are attending 
a hospital pain management clinic in NHS Grampian. To 
be eligible, participants will report severe pain, defined 
as a self- reported pain score of ≥7 out of 10 on the BPI 
‘pain on average’ rating item.30 We will include partici-
pants who have been stable on their usual pain medica-
tion; changes to medication (doses and type) will not be 
allowed during the study period. Patients receiving stable 
doses of duloxetine, gabapentin, pregabalin, amitripty-
line or nortriptyline will be included.
Patients taking antidepressants/psychotropic drugs 
which are not named above will be excluded. We will 
specifically exclude patients taking serotonin reuptake 
inhibitors such as fluoxetine or fluvoxamine and indi-
viduals taking nifedipine as there are known interactions 
with melatonin metabolism. We will exclude patients with 
abnormal baseline liver function tests, since this may affect 
the metabolism of melatonin. We will exclude patients 
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Figure 1 Study participant flow chart.
who are using benzodiazepines or non- benzodiazepine 
hypnotics (eg, zopiclone, zolpidem, zaleplon) because 
these medications can affect sleep measures. Similarly, we 
will exclude individuals with a history of drug or alcohol 
abuse or post- traumatic stress disorder. We will exclude 
any woman who is pregnant, breastfeeding or trying to 
conceive. Individuals with insufficient English to under-
stand trial information/procedures and any patient with 
known hypersensitivity to Circadin or any of its excipients 
will be excluded.
recruitment and consent
Potential participants due to attend pain clinics will be 
sent letters describing the study by their clinical team with 
a copy of the participant information sheet. All patients 
who attend the pain management clinic are routinely 
asked to complete the BPI on arrival. On arrival at clinic, 
the outpatient assistant or receptionist will also ask the 
patients whether they received the study letter and 
whether they are interested in speaking to their clini-
cian about the study. These patients will be highlighted 
to the clinical team who will then screen for eligibility. 
If eligible, interested patients will be asked if they would 
like to meet with a researcher who will explain the study 
and take written informed consent. A study visit date will 
then be arranged for recruited participants to attend the 
Clinical Research Unit at the University of Aberdeen.
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Period 2 week 0 
(study week 11)
Period 2 week 3 
(study week 14)
Period 2 week 6 
(study week 17)Outcome assessment
Demographics x
Serum melatonin x x x x x
Serum endogenous opioid x x x
VSH x x x x x x
PSQI x x x x x x
PSQ3 x x x x x x
BPI x x x x x x
PVT x x x x x x
Actimetry data download   x x x x x
Poststudy questionnaire   x
BPI, Brief Pain Inventory; PSQ-3, Pain and Sleep Questionnaire 3- item index; PSQI, Pittsburgh Sleep Quality Index; PVT, Psychomotor 
Vigilance Testing; VSH, Verran Snyder- Halpern Sleep Scale.
randomisation, allocation, blinding and data protection
The study team will have no access to participant data or 
medical records until the potential participant has been 
identified by the clinical team and has expressed interest 
in the study. Following eligibility screening and written 
informed consent, participants will be randomised in 
blocks of 10 (to minimise seasonal effects) to 1 of 2 groups: 
melatonin then placebo or placebo then melatonin.
The study drug or an identical placebo will be dispensed 
from the Clinical Trials Pharmacy, Aberdeen Royal Infir-
mary according to a previously supplied randomisation 
code list prepared by an independent statistician not 
involved in conducting the study. A paper copy of the 
randomisation code list is locked in a dedicated secure 
storage area within the Clinical Trials Pharmacy, and an 
electronic copy is held by the independent statistician on 
a secure computer server. Participants and all members 
of the research team will remain blinded to the treat-
ment allocation until after data analysis. Blinding will be 
maintained unless it is considered necessary to unblind 
for safety reasons. Participants will be allocated a unique 
participant identification (ID) number to protect their 
confidentiality throughout the study, and only the ID 
number will be used on study documentation. Identifi-
able patient information will be stored separately in a 
locked office with restricted access.
Blood samples will undergo secondary randomisation 
using a computer- generated system by an independent 
person not involved in the trial and given a unique spec-
imen code so that the sample analyst does not know the 
participant’s identity, sample number or visit date. This 
will maintain blinding.
Sample size
The primary outcome measure is improved sleep distur-
bance, measured using the Verran Snyder- Halpern (VSH) 
scale,31 which assesses sleep over the previous 24 hours. 
Our previous study showed that patients with mild pain 
(average pain score of 4 or less) compared with severe 
pain (scoring 7 or more) had median VSH sleep distur-
bance scores of 147 and 490, respectively.6 Assuming a 
conservative treatment effect difference of 120 (effect 
size=0.60), we need a minimum of 46 patients to achieve 
80% power.
Our main secondary outcome measure is pain inten-
sity. The Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials guidelines32 state that the 
minimum change in pain intensity following an interven-
tion that is clinically relevant is 2 points out of 10. We 
would need a minimum of 23 patients to demonstrate a 
change in average pain intensity of 2 points at 80% power. 
In anticipation of a 30% drop- out rate, we therefore plan 
to recruit 60 patients, with the aim of retaining 46 patients 
to trial completion.
Study outcomes
The study outcomes and timings of their assessment are 
shown in table 1. Participants will have six trial visits—at 
baseline (week 0); week 3; week 6; baseline after cross- 
over (after a 4- week washout period, study week 11); 3 
weeks after cross- over (study week 14) and 6 weeks after 
cross- over (study week 17). Participants will be tele-
phoned between each study visit that is, weeks 1, 2, 4, 5 15 
and 18, and at 4 weeks after completing the study to ask 
about any adverse effects.
The primary outcome is sleep disturbance in the last 
24 hours, which will be assessed using the VSH sleep scale. 
We will also assess sleep quality over the last month using 
the Pittsburgh Sleep Quality Index,33 pain- related sleep 
quality over the past week using the Pain and Sleep Ques-
tionnaire 3- item index34 and pain- related sleep interfer-
ence in the last week using the sleep interference item 
from the BPI.30 All sleep questionnaires will be conducted 
at baseline and at every subsequent visit (6 assessments in 
total over 20 weeks).
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Other secondary outcomes are: average pain intensity; 
activity levels; fatigue; alertness; serum melatonin levels; 
serum endogenous opioid peptide levels and partici-
pants’ views about taking part in the trial.
Average pain intensity will be measured using the BPI, 
which will be recorded at baseline and at each subsequent 
visit. We will use actigraphy to measure activity levels and 
sleep–wake cycle as well as daily patient- reported pain and 
fatigue ratings. Participants will be provided with the ‘Phil-
lips Spectrum Actiwatch PRO’, a "CE" marked (indicating 
European Economic Area trading conformity) wrist- worn 
actimeter, which they will be asked to wear throughout their 
whole participation in the trial. These devices concur with 
polysomnography, the gold standard for sleep studies,35 
and will also alert participants to rate pain and fatigue on a 
0–10- point subjective rating scale at 2000 hours every day. 
The device has sufficient memory and battery to support 
continuous recording for 4 weeks, but data will be down-
loaded at each study visit after baseline.
We will assess reduced alertness due to sleep loss using 
a personal computer- based psychomotor vigilance test 
(PVT)36 at baseline and during each subsequent study 
visit. The PVT requires sustained attention and measures 
how quickly subjects respond to a visual stimulus. A 
coloured number appears randomly every few seconds 
for 2 min and subjects click using an ultrafast gaming 
mouse as soon as the number appears. The software is 
freely available to download and incorporates data anal-
ysis capability.
Serum melatonin and its active metabolite, 
6- hydroxymelatonin sulfate will be measured using 
competitive ELISA at baseline and all subsequent visits. 
This will give insights into the adequacy of melatonin 
dosing and participant adherence/intervention fidelity. 
Endogenous opioid peptide levels will also be measured 
using ELISA at baseline and a further two study visits 
to assess potential mechanisms of analgesia associated 
with melatonin. Blinding will be maintained during all 
analyses.
Participants will be asked to complete a questionnaire 
about the trial at the final study visit and will be asked 
to indicate how onerous participation was using a series 
of questions and five- point Likert scale with ratings from 
strongly agree to strongly disagree. Participants will also 
be asked to indicate whether they thought they knew 
whether they had melatonin or placebo first and to indi-
cate a percentage improvement in sleep/reduction in 
pain that would lead them to choose to take melatonin 
regularly.
trial status
This trial is currently recruiting. Participant recruitment 
commenced on 26 July 2019 and is expected to finish 
recruiting on 8 April 2021. The approved protocol is 
version 2.0, 6 February 2019.
Statistical analysis
The statistical analyses will be conducted by Malachy 
Columb, who is based outside Aberdeen but who is part of 
the trial team. He will remain blinded to group allocation 
until after data analysis. Descriptive statistics will be calcu-
lated for all relevant variables. The effect of melatonin 
compared with placebo will be analysed on an intention- to- 
treat basis with treatment- received and per- protocol anal-
yses as required. Cross- over analyses will include tests for 
the effects of treatment, period, treatment–period inter-
action (carryover effect) and sequence. Within- patient 
effects and longitudinal data will be analysed using mixed 
linear models and the influences of confounders such as 
age, sex, numbers and classes of analgesics used will be 
assessed. Data will be analysed using Number Cruncher 
Statistical Systems (NCSS) V.11 (NCSS, Kaysville, Utah, 
USA) and StatXact V.9 (Cytel, Cambridge, Massachusetts, 
USA). Significance will be defined at p<0.05 (two sided).
trial conduct and monitoring
A trial steering committee (TSC) has been set up. The TSC 
comprises an external expert chair, a local expert and a 
lay representative. The role of the TSC is to provide over-
sight for the double- blind randomised controlled trial of 
exogenous administration of melatonin in chronic pain 
(DREAM- CP) study on behalf of the trial sponsor and 
the trial funder and to ensure that the trial is conducted 
according to the guidelines for Good Clinical Practice, 
Research Governance Framework for Health and Social 
Care and all relevant regulations and local policies. Each 
TSC member has signed a charter defining roles and 
responsibilities.
The Data Monitoring Committee (DMC) comprises 
two external clinical experts and an external statistical 
advisor. Their remit is to protect and serve DREAM- CP 
trial participants (especially their safety) and to assist and 
advise the investigators so as to protect the validity and 
credibility of the trial. The DMC will safeguard the inter-
ests of trial participants, assess the safety and efficacy of 
the interventions during the trial and monitor the overall 
conduct of the clinical trial. The DMC are independent 
from the sponsor. Each member of the DMC have signed 
a charter.
All adverse events, whether suspected to be treatment 
related or not, will be recorded. A research governance 
procedure is in place for reporting of serious adverse 
events/reactions to the sponsor and Medicines and 
Healthcare products Regulatory Agency (MHRA). All 
adverse events will also be reported to PharSafer. We do 
not plan to conduct interim analyses of our study data. 
Trial monitoring is being undertaken by NHS Gram-
pian and a plan has been agreed based on the trial risk 
assessment. Audit of the clinical trials pharmacy, standard 
operating procedures and laboratories is overseen by the 
quality assurance manager.
Patient and public involvement
Patients from the relevant population were involved in 
the study design stage itself. We shared the participant 
information sheet with our chronic pain patient liaison 
group and asked them to comment on both the clarity of 
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the information to be provided and their thoughts about 
the proposed trial generally. All patients felt the informa-
tion provided was clear and comprehensive and all said 
addressing sleep issues was important and they would be 
happy to take part. We also have lay representation on our 
trial steering group.
EthICS And dISSEMInAtIon
This study has been approved by Office for Research 
Ethics Committees Northern Ireland, reference 19/
NI/0007, and NHS Research and Development. The Inte-
grated Research Application System (IRAS) reference is 
255612. The study is a Clinical Trial of an Investigational 
Medical Product and a clinical trial authorisation was 
granted by MHRA reference 21583/0223/001–0001. Our 
results will be disseminated at relevant scientific meetings 
and published in a peer- reviewed journal. We will produce 
a poster displaying our results which will be displayed in 
the waiting area of the chronic pain clinic and posted to 
all participants. The study team also plan to disseminate 
results via local public engagement events organised by 
University of Aberdeen.
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